RecruitingNCT06623890
A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors
Studying Friedreich ataxia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Biogen
- Principal Investigator
- Medical DirectorBiogen
- Intervention
- Omaveloxolone(drug)
- Enrollment
- 300 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2024 – 2029
Study locations (14)
- UCLA Neurology, Los Angeles, California, United States
- University of Colorado, Aurora, Colorado, United States
- University of Florida, Gainesville, Florida, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Medizinische Universität Innsbruck, Innsbruck, Austria
- HUB-Hôpital Erasme, Brussels, Belgium
- Center for hereditary ataxias, Motol, Motol, Prague, Czechia
- Universitätsklinikum Tübingen, Tübingen, Baden-Würtemberg, Germany
- University Hospital Aachen, Aachen, Germany
- Klinikum der Universität München, Munich, Germany
- Scientific Institute, IRCCS E. Medea, Conegliano, Italy
- Fondazione I.R.C.C.S. Istituto Neurologico C. Besta, Milan, Italy
- Ospedale Pediatrico Bambino Gesu, Rome, Italy
- Stichting Radboud universitair medisch centrum, Nijmegen, Netherlands
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06623890 on ClinicalTrials.govOther trials for Friedreich ataxia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06628687A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their BabiesBiogen
- RECRUITINGNCT06865482Clinical Course Of Disease In Participants With FA-CMLexeo Therapeutics
- RECRUITINGPHASE3NCT06953583A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old (BRAVE)Biogen
- RECRUITINGPHASE1, PHASE2NCT06874010A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's AtaxiaDesign Therapeutics, Inc.
- RECRUITINGNCT07013292Efficacy of Omaveloxolone Treatment for Dysphagia in French Patients With Friedreich's AtaxiaCentre Hospitalier Universitaire de Nice
- RECRUITINGNANCT06692296Efficacy of Stabilometric Platform to Improve Standing Balance in Patients With Friedreich's AtaxiaIRCCS Eugenio Medea
- RECRUITINGPHASE1NCT06054893A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years OldBiogen
- RECRUITINGPHASE2NCT06447025An Open-Label Study of CTI-1601 in Subjects With Friedreich's AtaxiaLarimar Therapeutics, Inc.